Practical Strategies for the Responder: How to Address the Most Common (and Least Glamorous) Problem in Emergency Care
When we climb aboard the ambulance, we often expect adrenaline, sirens, and life-saving interventions. In the daily reality of emergency response, however, managing nausea represents a clinical challenge as common as it is underestimated. It may not be glamorous, but inadequate management can result in patients in distress, airway compromise, and logistical complications for the crew. This article proposes a practical, evidence-based approach that is, I hope, sufficiently pragmatic to address this problem between one pothole and the next.
Essential Background
Prevalence: 10-30% of patients in the EMS context experience nausea or vomiting.
Pathophysiology in brief: interaction between the chemoreceptor trigger zone, 5-HT₃ and D₂ receptors, and vagal stimulation. This is why targeted pharmacological choice makes a difference.
Clinical implications: risk of aspiration, dehydration, interference with monitoring, and operational inefficiency of the crew.
- Projectile emesis + headache → suspect ICP
- "Coffee ground" vomiting → GI bleed
- Chest pain → it's not just nausea
Antiemetic Tips and Tricks: The Winning Trio
When it comes to managing nausea and vomiting in the ambulance, having a clear strategy can truly make the difference between a smooth intervention and an unpleasantly chaotic one.
1. Isopropyl Alcohol (IPA)
The first intervention, simple and immediate, consists of bringing a gauze pad soaked in IPA close to the patient's nose, exploiting rapid olfactory stimulation with surprisingly quick efficacy (within 3-5 minutes). Often underestimated, recent 2023 meta-analyses demonstrate that its effectiveness can compete with 5-HT₃ receptor antagonist drugs, although with limited duration of action.
2. Ondansetron
If IPA is not sufficient, ondansetron clearly emerges as the first-line pharmacological option thanks to its ability to halve episodes of nausea and vomiting compared to metoclopramide, as demonstrated by recent 2025 meta-analyses. Available in various formulations (IV, IM, and ODT), it is a well-tolerated and effective drug, although requiring particular attention to QTc monitoring, which should not exceed 480 ms to avoid cardiac complications.
3. Metoclopramide
Metoclopramide remains a valid alternative, especially in contexts where ondansetron is not available or well tolerated. It is economical, widely available, and works well as a D₂ antagonist prokinetic agent, but attention must be paid to the maximum recommended dosage (30 mg/day) to avoid acute dyskinetic reactions.
4. Droperidol (Refractory Cases)
For the most refractory cases, droperidol can represent an effective rescue therapy, provided it is used with caution due to known adverse effects such as QTc prolongation and risk of hypotension. To be reserved for cases that truly test the crew's clinical skills.
Pharmacological Comparison
Intervention | Mechanism of Action | Clinical Considerations |
|---|---|---|
Inhaled IPA | Olfactory stimulation with rapid antiemetic effect (3-5 min). 2023 meta-analysis: efficacy comparable to 5-HT₃ antagonists | Limited duration of action. The odor may be unpleasant for unaccustomed personnel |
Ondansetron 4 mg IV/IM/ODT | Selective 5-HT₃ antagonist, reduces vomiting risk by 50% vs metoclopramide (2025 meta-analysis, n=861) | Essential QTc monitoring (contraindicated if > 500 ms) |
Metoclopramide 10 mg IV | Prokinetic agent with D₂ antagonist action, economical and widely available option | Risk of acute dyskinetic reactions. EMA limitation: max 30 mg/24h |
Droperidol 2.5 mg IV | High-potency D₂ antagonist, effective as rescue therapy | Caution for QTc prolongation and hypotension. Reserve for refractory cases |
Operational Protocol
- Assessment and red flags: vital parameters, ECG if long QT suspected.
- IPA aromatherapy immediately: soaked gauze near the nose.
- Ondansetron 4 mg IV/IM if moderate-severe nausea or IPA insufficient.
- Metoclopramide 10 mg IV if ondansetron not available or not tolerated.
- VAS-nausea monitoring every 5-10 min: watch for extrapyramidal effects or QTc alterations.
- Documentation: drug, dose, route of administration, pre/post VAS, attached ECG.
Five Practical Tips
IPA = starter pack. Fast, zero IV access, costs less than adhesive tape.
Ondansetron superstar. Effective, but remember the QT, especially if the monitor starts protesting.
Metoclopramide: yes, but with the hourglass. Maximum 30 mg/day.
Personalize. Pregnancy: assess benefit/risk ratio. Pediatrics: ondansetron 0.1 mg/kg.
It's not just medication. Lateral position, suction ready, fresh air. The patient thanks you. And so does your crew.
Focus on the Sumie et al. (2025) Study: New Evidence on Ondansetron Superiority
The recent meta-analysis by Sumie and colleagues, published in 2025 in the Journal of Anesthesia, offers important insights relevant also for the prehospital context. Although focused on the pediatric post-tonsillectomy setting (5 RCTs, n=861), the conclusions support the preferential use of ondansetron in the ambulance as well.
Key results transferable to the EMS context:
Relative risk reduction. Ondansetron reduces the risk of nausea/vomiting by 52% compared to metoclopramide (RR 0.48, 95% CI 0.31-0.75).
Efficacy independent of opioids. Regression analysis demonstrated that ondansetron's efficacy remains constant regardless of the dose of opioids administered.
Lower hospitalization. Reduced admission times (mean difference -26.92 minutes) in the ondansetron group.
Safety profile. Although only two studies monitored extrapyramidal reactions, no events were reported in either group.
These data, combined with EMS studies showing the growing adoption of ondansetron in prehospital protocols, confirm the advantage of using this drug in our setting. The 50% reduction in the risk of emetic episodes represents a significant advantage not only for patient comfort, but also for preventing complications such as aspiration, particularly risky during transport.
Conclusion
Effective management of nausea in the prehospital environment represents a fundamental aspect of daily clinical practice that, while not attracting media attention, has a significant impact on quality of care and patient safety.
A systematic approach that integrates IPA aromatherapy, targeted pharmacotherapy with ondansetron (or metoclopramide as an alternative), and appropriate positioning measures can transform a potentially traumatic experience into a manageable transport.
After all, we prefer that it be the patient who tells the story of their ambulance experience, not the contents of their stomach telling the story for them.
References
- Kimber JS, et al. Efficacy of isopropyl alcohol aromatherapy compared to 5-HT₃ antagonists for nausea management. Eur J Clin Pharmacol. 2023;79:1525-35.
- Sumie M, et al. Effect of ondansetron and metoclopramide on postoperative nausea and vomiting in children undergoing tonsillectomy with or without adenoidectomy: a systematic review with meta-analysis. J Anesth. 2025; epub ahead of print.
- European Medicines Agency. Metoclopramide: updated recommendations on use. 2013.
- Caffey MR, Maria S, Brewster L, Ireland MF. Antiemetic management preferences for paramedic providers: a cross-sectional survey. Australasian Journal of Paramedicine. 2016;13(2). doi:10.33151/ajp.13.2.217.
